Literature DB >> 6270267

Epstein-Barr virus-induced proteins. IV. Characterization of an EBV-associated phosphopolypeptide.

N Mueller-Lantzsch, N Yamamoto.   

Abstract

Cells of the Epstein--Barr virus (EBV) non-producing lines NC37 and Raji were induced by the tumour promoter TPA and were labelled with 32P. The analysis by immunoprecipitation with human VCA+EA+ sera revealed that a major phosphopolypeptide with a mol. wt. of 58 000 was specifically precipitated. In addition, a phosphopolypeptide of the same size was the dominant phosphopolypeptide detected in EBV-producing B95-8 and P3HR-1 cells as well as in P3HR-1-superinfected NC37 cells. This phosphopolypeptide seemed to be EBV-specific, because it was not detectable in TPA-treated, but EBV genome-negative, Ramos and BJAB cells. Synthesis of this phosphopolypeptide was inhibited in TPA-treated NC37 cells by treatment with Ara-C. VCA+EA+ sera were found to be more immunoreactive with this phosphopolypeptide than VCA+EA- or EBNA+ sera. Based on these results this phosphopolypeptide may have some immunological relatedness to the EBV-specific early antigen (EA) complex defined by immunofluorescence.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6270267     DOI: 10.1099/0022-1317-55-2-333

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  3 in total

1.  Expression of an early Epstein-Barr virus antigen (EA-D) in E. coli. Brief report.

Authors:  D Roeckel; H Boos; N Mueller-Lantzsch
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  Localization of the coding region for an Epstein-Barr virus early antigen and inducible expression of this 60-kilodalton nuclear protein in transfected fibroblast cell lines.

Authors:  M S Cho; K T Jeang; S D Hayward
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

3.  A second Epstein-Barr virus early antigen gene in BamHI fragment M encodes a 48- to 50-kilodalton nuclear protein.

Authors:  M S Cho; G Milman; S D Hayward
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.